Gilead taps Durham gene editing firm for $445M deal
September 13, 2018 at 15:07 PM EDT
California biotech Gilead Sciences (Nasdaq: GILD) has teamed up with a Durham-based Precision BioSciences to develop therapies targeting hepatitis B – a deal that could be worth $445 million.
